Jazz Pharmaceuticals plc
Simbolis: JAZZ
NASDAQ
124.79
USDRinkos kaina šiandien
16.5122
P/E santykis
0.0368
PEG koeficientas
7.78B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Jazz Pharmaceuticals plc (JAZZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5742.22 | 1626.3 | 881.5 | 591.4 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 930 | 420 | 30 | 0 | |||||||||||||||||||
balance-sheet.row.net-receivables | 2567.96 | 705.8 | 651.5 | 563.4 | |||||||||||||||||||
balance-sheet.row.inventory | 2540.86 | 597 | 714.1 | 1072.7 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 754.22 | 334.8 | 267.2 | 252.4 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 12304.18 | 3263.9 | 2606.1 | 2611.3 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1123.89 | 235 | 301.4 | 343.4 | |||||||||||||||||||
balance-sheet.row.goodwill | 6924.57 | 1753.1 | 1692.7 | 1827.6 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 22305.88 | 5418 | 5794.4 | 7152.3 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 29230.45 | 7171.2 | 7487.1 | 8979.9 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 25.24 | 4.7 | 5.5 | 12 | |||||||||||||||||||
balance-sheet.row.tax-assets | 1771.38 | 477.8 | 376.2 | 311.1 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 449.94 | 240.7 | 58.9 | 40.8 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 32600.91 | 8129.4 | 8229.1 | 9687.3 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 44905.09 | 11393.4 | 10835.3 | 12298.6 | |||||||||||||||||||
balance-sheet.row.account-payables | 436.48 | 102.8 | 90.8 | 100.3 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 1324.61 | 624.4 | 31 | 31 | |||||||||||||||||||
balance-sheet.row.tax-payables | 231.72 | 35.1 | 7.7 | 9.6 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 21794.59 | 5108 | 5765.2 | 6106.1 | |||||||||||||||||||
Deferred Revenue Non Current | 64.26 | 64.3 | 0 | 0.5 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 3531.91 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 3168.01 | 774.5 | 811 | 675.9 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 25853.81 | 6119.7 | 6816.3 | 7524.1 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 297.5 | 64.3 | 71.8 | 87.2 | |||||||||||||||||||
balance-sheet.row.total-liab | 30818 | 7656.4 | 7749.5 | 8333.4 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 0.24 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 3377.81 | 878.7 | 733.6 | 830.2 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -3724.13 | -841.7 | -1125.5 | -400.4 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 14433.16 | 3700 | 3477.6 | 3535.3 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 14087.09 | 3737 | 3085.7 | 3965.2 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 44905.09 | 11393.4 | 10835.3 | 12298.6 | |||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-equity | 14087.09 | 3737 | 3085.7 | 3965.2 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 44905.09 | - | - | - | |||||||||||||||||||
Total Investments | 940.2 | 424.7 | 35.5 | 12 | |||||||||||||||||||
balance-sheet.row.total-debt | 23183.46 | 5796.7 | 5796.2 | 6137.1 | |||||||||||||||||||
balance-sheet.row.net-debt | 18191.25 | 4590.3 | 4914.7 | 5545.7 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 414.83 | 414.8 | -224.1 | -329.7 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 638.7 | 638.7 | 629.5 | 552.5 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | -260.22 | -260.2 | -292.3 | 69.2 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 226.84 | 226.8 | 222 | 189 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -204.44 | -204.4 | 9.9 | -48 | |||||||||||||||||||
cash-flows.row.account-receivables | -51.88 | -51.9 | -90.1 | -92.7 | |||||||||||||||||||
cash-flows.row.inventory | -13.42 | -13.4 | -49.6 | -48.9 | |||||||||||||||||||
cash-flows.row.account-payables | 9.6 | 9.6 | -11.2 | 57 | |||||||||||||||||||
cash-flows.row.other-working-capital | -148.74 | -148.7 | 160.9 | 36.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 276.29 | 276.3 | 926.9 | 345.4 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1092.01 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -24.96 | -24 | -498.2 | -45.5 | |||||||||||||||||||
cash-flows.row.acquisitions-net | -20 | 0 | 53 | -6234.8 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -390.1 | -390.1 | -61 | -26.8 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 270 | 270 | 60 | 1095 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 2 | -19 | 0 | 0 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -163.06 | -163.1 | -446.2 | -5212.1 | |||||||||||||||||||
cash-flows.row.debt-repayment | -31 | -31 | -582 | -1320.6 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 46.46 | 46.5 | 98 | 135.3 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | -313.03 | -269.8 | -0.1 | -35.6 | |||||||||||||||||||
cash-flows.row.dividends-paid | -112.28 | 0 | -98 | -99.7 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 104.59 | -51 | 52.6 | 5291.1 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -305.25 | -305.3 | -529.5 | 3970.5 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.14 | 1.1 | -6.2 | -3.2 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 634.83 | 354.8 | 290 | -466.3 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 4992.22 | 1206.3 | 881.5 | 591.4 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 4357.39 | 851.5 | 591.4 | 1057.8 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 1092.01 | 1092 | 1272 | 778.5 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -24.96 | -24 | -498.2 | -45.5 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 1067.05 | 1068 | 773.8 | 733 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3834.2 | 3834.2 | 3659.4 | 3094.2 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 587.13 | 1043.9 | 540.5 | 440.8 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 3247.07 | 2790.3 | 3118.9 | 2653.5 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 849.66 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 1286.53 | 1476.9 | 599.2 | 525.8 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 2587.77 | 2131.1 | 2606.6 | 2483.2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 3174.9 | 3174.9 | 3147.1 | 2924 | ||||||||||||||||||||
income-statement-row.row.interest-income | 65.2 | 65.1 | 11.5 | 1.8 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 308.77 | 351.1 | 288.2 | 278.8 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -215.41 | -361.4 | -885.1 | -283.1 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 1286.53 | 1476.9 | 599.2 | 525.8 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -215.41 | -361.4 | -885.1 | -283.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 308.77 | 351.1 | 288.2 | 278.8 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 632.12 | 638.7 | 599.2 | 525.8 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 1290.43 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 658.31 | 659.3 | 512.3 | 170.3 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 297.93 | 297.9 | -372.8 | -112.8 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | -119.91 | -119.9 | -158.6 | 216.1 | ||||||||||||||||||||
income-statement-row.row.net-income | 414.83 | 414.8 | -214.1 | -329 |
Dažnai užduodami klausimai
Kas yra Jazz Pharmaceuticals plc (JAZZ) bendras turtas?
Jazz Pharmaceuticals plc (JAZZ) bendras turtas yra 11393359000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 1984075000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.847.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 17.051.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.108.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.172.
Kas yra Jazz Pharmaceuticals plc (JAZZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 414832000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 5796653000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 2131063000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 1206310000.000.